Background-Heart failure is associated with neurological deficits, including cognitive dysfunction. However, the molecular mechanisms underlying reduced cerebral blood flow in the early stages of heart failure, particularly when blood pressure is minimally affected, are not known. Methods and Results-Using a myocardial infarction model in mice, we demonstrate a tumor necrosis factor-␣ (TNF␣)-dependent enhancement of posterior cerebral artery tone that reduces cerebral blood flow before any overt changes in brain structure and function. TNF␣ expression is increased in mouse posterior cerebral artery smooth muscle cells at 6 weeks after myocardial infarction. Coordinately, isolated posterior cerebral arteries display augmented myogenic tone, which can be fully reversed in vitro by the competitive TNF␣ antagonist etanercept. TNF␣ mediates its effect via a sphingosine-1-phosphate (S1P)-dependent mechanism, requiring sphingosine kinase 1 and the S1P 2 receptor. In vivo, sphingosine kinase 1 deletion prevents and etanercept (2-week treatment initiated 6 weeks after myocardial infarction) reverses the reduction of cerebral blood flow, without improving cardiac function. Conclusions-Cerebral artery vasoconstriction and decreased cerebral blood flow occur early in an animal model of heart failure; these perturbations are reversed by interrupting TNF␣/S1P signaling. This signaling pathway may represent a potential therapeutic target to improve cognitive function in heart failure. (Circulation. 2012;126:196-206.)
Clinical Perspective on p 206
Blood flow autoregulation relies on the property of cerebral arteries to adjust their flow resistance, via changes in vessel diameter, to the prevalent transmural pressure (ie, the myogenic response or Bayliss effect 6, 7 ) and to maintain constant CBF over a wide range of systemic pressures (60-to 150-mm Hg mean arterial pressure). 8 To ensure that CBF regulation has fine spatial resolution (ie, the ability to precisely and selectively increase flow to active brain volumes), different branch generations of the cerebrovascular tree are structurally and functionally specialized. The distal resistance arteries, which are located just before the capillary beds, exhibit the largest degree of myogenic activity and integrate modulatory influences of tissue-derived signaling molecules. 9 Proximal cerebral arteries minimally restrict blood flow (ie, maintain a low-resistance profile) and ultimately display a functional pattern very similar to that of conduit arteries in the systemic circulation (ie, minimal myogenic activity). Therefore, high levels of myogenic tone in proximal cerebral arteries may result in widespread reductions in CBF.
With regard to the molecular basis for the myogenic response, sphingosine-1-phosphate (S1P) signaling has emerged as a central pathway in several vascular beds, including cerebral arteries. 10 -12 The proconstrictive effects of S1P are mediated primarily via the S1P 2 receptor, [11] [12] [13] which activates RhoA/Rho kinase and ultimately inhibits myosin light-chain phosphatase. 14 The central element of this pressure-sensitive signaling pathway in smooth muscle cells is sphingosine kinase 1 (Sphk1), which generates S1P. Thus, factors known to modulate Sphk1 activity are candidates for altering myogenic responsiveness.
The inflammatory cytokine tumor necrosis factor-␣ (TNF␣) is a well-characterized activator of Sphk1 [15] [16] [17] and a hallmark of several cardiovascular 18, 19 and cerebrovascular 20 -22 diseases. Indeed, recent in vitro measurements using the spiral modiolar artery (a cochlear artery) indicate that TNF␣ activates smooth muscle cell Sphk1 to induce a proconstrictive state throughout the cochlear microcirculation. 23 In addition, TNF␣ has been shown to elicit vasoconstriction in both human mammary arteries 24 and mouse cerebral arteries. 25 However, the ability of TNF␣ to link a systemic disease like HF to altered control of CBF had not been explored.
Here, we show that proximal cerebral arteries, which normally possess minimal myogenic activity, are recruited to become myogenically active in HF and that TNF␣ is the primary factor driving this recruitment through activation of S1P signaling. Our results provide a microvascular concept that explains the association between HF and the decrease in CBF.
Methods

Mouse Nomenclature
All wild-type mice used in this investigation were commercially available C57BL/6N mice. Mice lacking Sphk1 (Sphk1 Ϫ/Ϫ ), sphingosine kinase 2 (Sphk2 Ϫ/Ϫ ), the S1P 2 receptor subtype (S1P 2 R Ϫ/Ϫ ), and a double mutant with complete deletion of Sphk1 and heterozygosity for Sphk2 (Sphk1 Ϫ/Ϫ /Sphk2 Ϯ ) were kindly provided by Dr Richard L. Proia (Bethesda, MD). Unless otherwise designated, arteries were isolated from naïve mice; all mice operated on to induce HF or to create a sham controls were designated as such.
Myocardial Infarction
HF in mice was induced by experimental myocardial infarction produced by permanent surgical ligation of the left anterior descending coronary artery (LAD), as previously described. 12 In sham-operated controls, the thorax and pericardium were opened, but the LAD was not ligated. After either procedure, the chest was closed and the mice were extubated on spontaneous respiration. Cerebral arteries were isolated 4 to 6 weeks after myocardial infarction. As described, HF (infarct size approximating 25% of the left ventricular wall) mice develop enlarged hearts, congested lungs, reduced CO and blood pressure, and elevated peripheral resistance. 12 All of these parameters remain normal in shamoperated controls.
Isolation and Functional Assessment of Cerebral Arteries
To demonstrate the longitudinal gradient of myogenic activity, posterior cerebral artery (PCA) segments from healthy gerbils were used; distal segments of gerbil PCAs were more reliable for experimentation, because of less frequent branching. All other experiments used proximal PCA segments from the mouse. After anesthesia, the animal was decapitated, and the brain was rapidly removed from the cranium and immersed in ice-cold sterile 3-(n-morpholino)propanesulfonic acid (MOPS) buffer. PCA segments (0.8 -1.0 mm in length) were carefully dissected from the surrounding connective tissue. Only first-order vessels were isolated from mice (160 -220 m), whereas first-and third-or fourth-order vessels were harvested from gerbils (160 -220 and 90 -150 m in diameter, respectively). The isolated vessel segments were cannulated on glass micropipettes, stretched to their in vivo lengths, and pressurized to 45 mm Hg, as previously described. 26 All functional experiments were conducted in MOPS-buffered saline at 37°C with no perfusion.
To measure myogenic responses, vessels were subjected to stepwise increases in transmural pressure (20-mm Hg increments) from 20 to 100 mm Hg. At each pressure step, vessel diameter (dia active ) was measured once a steady state was reached (3-5 minutes). Myogenic tone was calculated as the percent constriction in relation to the maximal diameter at each respective transmural pressure: tone (percent of dia max )ϭ[(dia max Ϫdia active )/dia max ]ϫ100, where dia active is the vessel diameter in MOPS containing Ca 2ϩ and dia max is the diameter in Ca 2ϩ -free MOPS. Vasomotor responses (eg, phenylephrine, acetylcholine, Ca 2ϩ sensitivity) used the same calculation, only in these cases, dia active represents the vessel diameter at steady state after application of the given agent and dia max represents the maximal diameter (measured under Ca 2ϩ -free conditions) at 45 mm Hg. Further details are provided in the online-only Data Supplement, and representative tracings are shown in Figure I 
Immunohistochemistry and Reverse Transcriptase-Polymerase Chain Reaction
Standard immunohistochemical and biochemical procedures were used. Detailed methods are provided in the online-only Data Supplement.
Cerebral Blood Flow
A noninvasive magnetic resonance imaging-based method known as the flow-sensitive alternating inversion recovery technique was used to evaluate brain perfusion. 27 This technique is described in detail in the online-only Data Supplement. Briefly, the approach isolates perfusion as an accelerated T1 signal relaxation. Magnetic resonance imaging signals were acquired from vertical sections of the forebrain, midbrain, and hindbrain, which correspond to the anterior, mixed, and posterior circulations. Flow-sensitive alternating inversion recovery images were evaluated for designated regions of interest by the use of standardized algorithms and image processing procedures (MIPAV; National Institutes of Health, Bethesda, MD; http://www.mipav.cit.nih.gov/).
Etanercept Treatment In Vivo
Six weeks after myocardial infarction, cohorts of HF mice were treated with either etanercept (1 mg/mL sc) or saline twice weekly for 2 weeks. Sham-operated mice served as controls. CBF 27 and hemodynamic parameters 12 were assessed as previously described.
Statistical Analysis
All data (including figures) are expressed as meanϮSEM, where n is the number of vessels studied. An unpaired Student t test was used to compare 2 separate groups (eg, sham and HF). When appropriate (eg, before and after inhibitor), a paired Student t test was used. For comparison of multiple groups, an ANOVA followed by t tests with Bonferroni correction was used. Differences were considered significant at PϽ0.05.
Results
Magnetic Resonance Imaging-Demonstrable Reductions in CBF Occur Early in HF
CBF was measured in predefined cortical and subcortical regions of interest, and pooling of data from all regions of interest was used to assess global CBF in sham (nϭ14) versus HF (4 -6 weeks after myocardial infarction; nϭ16) mice. Global (227Ϯ10 versus 165Ϯ8 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 ; PϽ0.05), cortical (213Ϯ11 versus 163Ϯ7 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 ; PϽ0.05), and subcortical (226Ϯ14 versus 185Ϯ17 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 ; PϽ0.05) CBF was reduced in HF mice ( Figure 1 ). Importantly, these reductions in CBF were not attributable to any changes in brain structure, as measured by high-resolution magnetic resonance imaging ( Figure II in the online-only Data Supplement). Moreover, at this early stage of HF, mice did not manifest 
HF Is Associated With Increased Myogenic Tone in Proximal Cerebral Arteries
In the gerbil, a larger animal enabling comparisons between proximal and distal cerebral vessels, we found that distal (third-or fourth-order) segments of the PCA normally exhibit greater resting tone (defined as tone at 45 mm Hg; distal, 7.1Ϯ2.7%; proximal, 1.9Ϯ0.2%; nϭ6; PϽ0.05) and significantly stronger myogenic tone at each applied pressure step (defined as tone over a range of 20 -100 mm Hg in 20mm Hg increments) compared with proximal (first-order) segments ( Figure 2A ).
In contrast, in mice with HF, both resting tone (sham, 3.0Ϯ0.3%, nϭ6; HF, 5.7Ϯ0.9%, nϭ12; PϽ0.05) and myogenic tone ( Figure 2B ) were significantly increased in proximal PCAs compared with sham-operated controls; passive external diameters did not differ (dia max : sham, 197Ϯ2 m, nϭ6; HF, 195Ϯ3 m, nϭ14; PϭNS).
Increased PCA Expression of TNF␣ Accounts for Enhanced Myogenic Tone in HF
Costaining of brain slices revealed increased TNF␣ expression in PCAs from mice with HF compared with sham controls ( Figure 3A ). This increased TNF␣ expression appeared to be localized primarily to the smooth muscle compartment within the microvascular wall (virtually complete overlap of TNF␣ with smooth muscle ␣-actin staining; Figure 3B ). Reverse transcriptase-polymerase chain reaction experiments using isolated PCAs confirmed a 2.5-fold increase in TNF␣ mRNA in HF versus sham ( Figure 3C ).
In PCAs isolated from wild-type mice with HF, etanercept (a competitive TNF␣ antagonist) fully normalized HFstimulated enhancement of myogenic tone (nϭ6; Figure 3D ). Consistent with this observation, treatment of PCAs isolated from naïve wild-type mice with TNF␣ (50 pg/mL for 30 minutes) stimulated a significant increase in both resting tone (2.4Ϯ0.1% versus 4.5Ϯ0.5%; nϭ5; PϽ0.05, paired comparison) and myogenic tone ( Figure 3E ). Subsequent cotreatment with the putative S1P 2 R antagonist JTE013 (1 mol/L for 30 minutes) abolished the TNF␣-mediated increase in resting tone (2.7Ϯ0.4%; PϭNS, paired comparison with control) and myogenic tone ( Figure 3E ).
TNF␣ Increases Myogenic Tone in Mouse PCA via Sphk1 and S1P 2 R
On the basis of our observation that an S1P 2 R antagonist abolished TNF␣-enhanced tone in PCAs from wild-type animals without HF, we hypothesized that the increased myogenic tone of PCAs from mice with HF might also be mediated by enhanced S1P/S1P 2 R signaling via the known TNF␣-dependent activation of the enzyme sphingosine kinase (Sphk). [15] [16] [17] 23 First, we confirmed that a low concentration of S1P (10 nmol/L, which does not stimulate vasoconstriction) has the ability to enhance resting and myogenic tone in wild-type mouse and gerbil PCAs ( Table I in the onlineonly Data Supplement). Next, using loss-of-function mice (please note that the Sphk1 Ϫ/Ϫ /Sphk2 Ϫ/Ϫ double knockout is embryonically lethal), we observed that TNF␣ had no effect on PCAs from Sphk1 Ϫ/Ϫ , Sphk1 Ϫ/Ϫ /Sphk2 ϩ/Ϫ , or S1P 2 R Ϫ/Ϫ mice ( Figure 4 ). In contrast, TNF␣ stimulated a 2-to 3-fold increase in myogenic tone in mice lacking Sphk2 ( Figure 4A ).
Enhanced Myogenic Tone in the PCA in HF Is Mediated by Activation of S1P Signaling
Unlike wild-type mice ( Figure 2B ), HF failed to augment myogenic tone in mice lacking Sphk1 ( Figure 5A ). Importantly, the application of exogenous S1P (3 mol/L) restored the HF phenotype and enhanced myogenic tone in PCAs isolated from both HF and sham Sphk1 Ϫ/Ϫ mice to similar extents ( Figure 5A ). Passive external diameters were not different (dia max : Sphk1 Ϫ/Ϫ sham, 174Ϯ7 m, nϭ6; Sphk1 Ϫ/Ϫ HF, 173Ϯ8 m, nϭ5; PϭNS; Figure 5A ). Our model of HF also failed to increase myogenic tone in mice lacking the S1P 2 receptor (S1P 2 R Ϫ/Ϫ ; Figure 5B ). Again, passive diameters did not differ (dia max : S1P 2 R Ϫ/Ϫ sham, 186Ϯ13 m, nϭ5; S1P 2 R Ϫ/Ϫ HF, 191Ϯ4 m, nϭ6; PϭNS; Figure 5B ). As with the TNF␣-mediated enhancement of myogenic tone ( Figure 3E ), JTE013 reversed the HF-stimulated enhancement of myogenic tone observed in PCAs from wild-type mice ( Figure 5C ).
Taken together, these data demonstrate that the enhanced myogenic tone of PCAs that occurs in HF requires an intact S1P signaling system. To further establish the specificity of our earlier observations with the TNF␣ antagonist etanercept ( Figure 3D ), we tested the effects of this agent in mice lacking components of S1P signaling. Etanercept had no effect on PCAs isolated from Sphk1 Ϫ/Ϫ or Sphk1 Ϫ/Ϫ / Sphk2 ϩ/Ϫ mice with HF ( Figure IV in the online-only Data Supplement). Although a small effect of etanercept was observed in PCAs from S1P 2 R Ϫ/Ϫ mice with HF ( Figure V in the online-only Data Supplement), it was not enough to account for the complete normalization of myogenic tone observed in PCAs from wild-type mice with HF ( Figure 3D ).
HF Specifically Enhances S1P-Stimulated PCA Vasoconstriction
We next examined whether HF was associated with indiscriminate (ie, systematic) increases in PCA responsiveness or a more exclusive sensitivity to S1P. PCAs from sham mice displayed minimal vasoconstriction in response to exogenously applied S1P (30 nmol/L to 3 mol/L; Figure 6A ), whereas PCAs from HF mice displayed robust dose-dependent vasoconstrictor responses to S1P ( Figure 6A ). In contrast, dose-response relationships for phenylephrine (log EC50 : HF, Ϫ5.33Ϯ0.34; sham, Figure 3 . Tumor necrosis factor-␣ (TNF␣) mediates the heart failure (HF)-induced increase in posterior cerebral artery (PCA) myogenic tone. A, Brain slices from HF and sham-operated animals containing a cross section of the PCA were costained with Hoechst 33258 (to identify cell nuclei) and antibodies against smooth muscle ␣-actin (sm ␣-actin) and TNF␣. TNF␣ expression was increased homogeneously throughout the PCA vessel wall in HF mice (overlay). B, High-magnification confocal images demonstrate that the vast majority of TNF␣ expression was localized to the smooth muscle layer (colocalization of sm ␣-actin and TNF␣ generates yellow); TNF␣ expression was not observed in the endothelial (thin arrows identify endothelial nuclei) or adventitial (thick arrow identifies adventitial nuclei) layers. C, TNF␣ mRNA expression was higher in isolated PCAs from HF mice compared with sham-operated animals (nϭ4, each). D, The TNF␣ antagonist etanercept (ETN; 10 g/mL for 30 minutes; dia max ϭ194Ϯ3 m; nϭ6) normalized the HF-mediated increase in myogenic tone. E, TNF␣ (50 pg/mL for 30 minutes) stimulated a significant enhancement of myogenic tone in wild-type PCAs that was reversed by subsequent treatment with JTE013 (1mol/L for 30 minutes; nϭ5). TMP indicates transmural pressure.
Ϫ5.33Ϯ0.27; PϭNS; nϭ4 each; Figure 6B ) and Ca 2ϩ under depolarizing (120 mmol/L K ϩ ) conditions (log EC50 : HF, Ϫ3.28Ϯ0.05; sham, Ϫ3.31Ϯ0.05; PϭNS; nϭ4 each; Figure  6C ) were not affected by HF.
Lack of Sphk1 ؊/؊ Protects Against the HF-Induced Reduction in CBF
Our in vitro data predict that disrupting S1P signaling will ameliorate the HF-induced reduction in CBF. LAD ligation profoundly compromised cardiac performance in Sphk1 Ϫ/Ϫ mice, as evidenced by substantial reductions in stroke volume and CO (Table II in the online-only Data Supplement). A compensatory increase in total peripheral resistance maintained mean arterial pressure (MAP) in Sphk1 Ϫ/Ϫ mice, with HF at levels comparable to those in sham-operated mice ( Table II in the online-only Data Supplement). Although MAP levels appeared to be lower than in the other tested cohorts, these observations are unlikely to be attributable to the Sphk1 Ϫ/Ϫ genotype. 28 Because autoregulation serves to maintain organ blood flow during fluctuations in perfusion pressure, the observed lack of correlation between CBF and MAP in Sphk1 Ϫ/Ϫ sham and HF mice indicates that autoregulatory mechanisms were functioning under both conditions (Figure 7) . Despite intact autoregulation, CBF measures were qualitatively lower than in the other cohorts, suggesting the presence of a specific Sphk1 Ϫ/Ϫ phenotype. Our experimental design, however, did not include wild-type littermate controls; thus, we limit our analyses strictly to the sham and HF groups within the Sphk1 Ϫ/Ϫ cohort. In this specific context, HF did not alter CBF in Sphk1 Ϫ/Ϫ mice ( Figure 7C ), so we conclude that Sphk1 is an integral component of the signaling pathway that reduces CBF in HF. 
Systemic Etanercept Treatment of Mice in HF Improves Global CBF
We next attempted to therapeutically target the identified molecular pathway driving reduced CBF. In the absence of a clinically available S1P signaling antagonist, we used etanercept, a clinically available TNF␣ antagonist.
In initial experiments, the etanercept treatment was started 2 weeks after LAD ligation (1 mg/mL sc twice per week for 6 weeks). Etanercept treatment fully reversed the reduction in global CBF observed in HF (sham saline, 220Ϯ8 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 , nϭ8; HF saline: 189Ϯ7 mL/100 g ⅐ min, nϭ8;
HFϩetanercept, 228Ϯ5 mL ⅐ 100 g Ϫ1 ⅐ min Ϫ1 , nϭ7; PϽ0.05, HF versus sham or HFϩetanercept; Table III in the onlineonly Data Supplement). However, this regimen also positively affected cardiac function ( Table III in the online-only Data Supplement), making it difficult to attribute the positive outcome unambiguously to a vascular mechanism.
In subsequent experiments, etanercept treatment was initiated 6 weeks after LAD ligation (1 mg/mL sc twice per week for 2 weeks), under the premise that the heart injury would be more permanent at later time points following myocardial infarction. Indeed, this revised treatment regimen did not improve cardiac function (eg, CO, LVEF, stroke volume; Table IV in the online-only Data Supplement) but continued to restore CBF (Figure 8 ; representative flow-sensitive alternating inversion recovery-magnetic resonance imaging flow maps are displayed in Figure VI in the online-only Data Supplement).
Although both CO (inversely) and total peripheral resistance (positively) showed tight correlation with infarct size, MAP did not (Figure 8) . Similarly, CBF was inversely correlated with infarct size but not MAP; instead, CBF was negatively correlated with calculated values for cerebral resistance (MAP/CBF). In contrast, etanercept-treated mice (6 weeks after LAD ligation; nϭ8) displayed no correlations between CBF and infarct size, CBF, and MAP or between cerebral resistance and infarct size.
Discussion
This investigation demonstrates that HF induces a widespread peripheral vascular response that includes an alteration in CBF autoregulation. In response to reduced CO, total peripheral resistance increases, 29, 30 which maintains MAP well within the acceptable range for blood flow autoregulation (ie, 60 -150 mm Hg). 8 This compensatory mechanism explains why MAP does not correlate with infarct size ( Figure 8C ).
Because MAP is maintained within the autoregulatory range, the observed reductions in CBF cannot be attributed to systemic hemodynamic parameters. The absence of a relationship between MAP and CBF in HF ( Figure 8E ) demonstrates that CBF autoregulation persists under these conditions, with reductions in CBF resulting from altered autoregulatory mechanisms within the cerebral microcirculation (ie, increased resistance at a given MAP). Together, these data suggest that HF induces a compensatory vascular response that serves to maintain MAP by elevating total peripheral resistance. CBF autoregulation is not exempted from this response. Indeed, the degree to which cerebral resistance increases is tightly correlated with the degree of heart injury (ie, infarct size; Figure 8F ).
The reduction in CBF observed in this investigation is consistent with clinical reports in HF patients. [1] [2] [3] [4] Reduced perfusion of the brain would be expected to cause wideranging neurological effects; indeed, cognitive symptoms, including impairment of memory, attention, mental flexibility, and global cognitive functions, are clinically observed in 40% to 60% of patients with late-stage HF. 1, 2, 31, 32 The 25% CBF reduction observed in the present investigation, however, is below the reported threshold [33] [34] [35] [36] necessary to cause cognitive deficits or gross morphological changes and explains their absence in the present model.
In vitro, we confirm that a longitudinal gradient of myogenic activity exists within the cerebrovascular tree; proximal arteries display minimal myogenic tone, whereas the more distal sections possess substantial myogenic activity. Our results support the premise that proximal PCA branches do not play a primary role in adjusting CBF under normal physiological conditions. In HF, their phenotype changes: they display augmented myogenic tone that, under physiological conditions, is more characteristic of distal regions. In essence, myogenic reactivity and consequently microvascular resistance to blood flow extends to the proximal regions of the vascular tree, resulting in reduced cerebral blood supply.
The recruitment of PCAs into the myogenic chain results from an autocrine/paracrine effect of TNF␣, which is released from PCA vascular wall. Although TNF␣ has a welldocumented role in stroke 37 and HF, 18, 19 further studies are required to determine how HF actually activates TNF␣ in the PCA. Of note, we recently implicated TNF␣-dependent signaling in the cochlear microcirculation as a pathogenic stimulus in sensorineuronal hearing loss. 23 The vascular effects of TNF␣ are generally attributed to increased serum levels of the cytokine; however, the present study demonstrates that HF induces an upregulation of TNF␣ mRNA and protein expression within the vascular wall of PCAs, with the vast majority of protein localized to the smooth muscle layer. We therefore propose that TNF␣ (or more specifically, the relevant pool of smooth muscle cell TNF␣) acts in an autocrine/paracrine manner to enhance PCA smooth muscle cell contractility. This would explain why explanted PCAs retain their altered phenotype, characterized by augmented myogenic tone, over several hours ex vivo. Sequestering vessel wall TNF␣ with etanercept restores tone in HF PCAs to sham levels, confirming that TNF␣ is causally involved in the tone-enhancing mechanism and that the vessel wall is the source of TNF␣. Accordingly, exogenously applied TNF␣ induces the same phenotype shift in isolated proximal PCAs from naïve mice that was observed in HF mice (ie, from minimal to robust myogenic tone).
The molecular pathway that links TNF␣ to enhanced myogenic tone is the S1P signaling pathway. Consistent with our previous observations, 14 S1P signaling is a key regulator of myogenic tone [11] [12] [13] and is essential for the HF-mediated increase in proximal PCA myogenic tone. Using knockout models, we show that exogenous TNF␣, a known activator of Sphk1, [15] [16] [17] mediates its effects via Sphk1 and S1P 2 R. Specifically, isolated PCAs from mice lacking Sphk1 (Sphk1 Ϫ/Ϫ ), Sphk1, and 1 allele of Sphk2 (Sphk1 Ϫ/Ϫ /Sphk2 Ϯ ) or S1P 2 R (S1P 2 R Ϫ/Ϫ ) do not have increased myogenic tone in response to TNF␣.
The deletion of Sphk1 abolishes the HF-induced augmentation of PCA myogenic tone (measured in vitro) and protects against HF-mediated reductions in CBF and changes in CBF autoregulation. Genetic deletion of S1P 2 R also abolished the HF-induced augmentation of myogenic tone in isolated PCAs. JTE013 reverses both the TNF␣-and HF-mediated increase in myogenic tone. Although JTE013 is a putative S1P 2 R antagonist, we observed clear S1P 2 R-independent effects ( Figure VII in the online-only Data Supplement). 38 Nevertheless, JTE013 appears to retain specificity for S1P signaling (ie, does not inhibit endothelin-1 or phenylephrine responses), 12, 23 making it suitable for investigating the contributions of S1P receptors, despite an inability to discern the specific role of S1P 2 R. Taken together, our data support that TNF␣ mediates its effects via S1P signaling, a conclusion that is further substantiated by our observation that TNF␣ sequestration (etanercept) is without effect in isolated PCAs with disrupted S1P signaling.
To therapeutically translate our in vitro data, we targeted TNF␣ in vivo with the clinically available agent etanercept. By delaying treatment to 6 weeks after LAD ligation, we mitigated the beneficial effects of etanercept on cardiac function (compare Tables II and III in the online-only Data Supplement). In the absence of improved cardiac function, we are able to unambiguously attribute the restored CBF to altered vascular function. We found that etanercept treatment broke the link between heart injury and cerebrovascular resistance/CBF (ie, eliminated the correlations observed in saline-treated HF mice; Figure 8 ). Importantly, we continued to observe no correlation between MAP and CBF in etanercept-treated mice with HF, indicating the normalization of autoregulation.
Significantly, although etanercept improved CBF autoregulation, it did not meaningfully alter total peripheral resistance (Table IV) . This suggests that etanercept treatment acts selectively on certain microvascular beds during HF and positions the treatment as a possible strategy to discretely improve blood flow in critical organs (eg, the brain) during HF. Critical organ perfusion was not assessed in the Randomized Etanercept North American Strategy to Study Antagonism of Cytokines (RENAISSANCE) and Research Into Etanercept Cytokine Antagonism in Ventricular Dysfunction (RECOVER) clinical trials, which were halted prematurely owing to a lack of beneficial effects on the end points of clinical composite score, HF hospitalization, and mortality. 39 Importantly, these trials also showed that etanercept did not worsen the clinical outcome of HF. 39 This finding encourages a reexamination of this pathway for the improvement or prevention of cerebral perfusion deficits in HF.
Conclusions
We demonstrate that TNF␣ recruits proximal cerebral arteries into a myogenic phenotype, resulting in comprised autoregulation and restricted CBF. We demonstrate that TNF␣ mediates the enhancement of PCA tone via Sphk1/S1P 2 R signaling, all of which deserve evaluation as potential therapeutic targets for the improvement of CBF in HF patients. Indeed, our data show that the in vivo use of etanercept fully restores CBF in mice with HF. We propose that etanercept treatment restores the minimally restrictive phenotype of PCAs and shifts autoregulatory function back to the distal regions of the cerebral microcirculation.
